Published in Physician Law Weekly, May 9th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Callisto Pharmaceuticals.
Report 1: Callisto Pharmaceuticals, Inc., (KAL; CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced the opening of a second clinical site, the Dana-Farber Cancer Institute in Boston, Massachusetts, for its phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine carcinoma (advanced carcinoid cancer).
The Principal Investigator at the Dana-Farber Cancer Institute is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly